Real-world experience of hereditary angioedema (HAE) in Mexico: A mixed-methods approach to describe epidemiology, diagnosis, and treatment patterns

INTRODUCTION AND OBJECTIVES: Due to the lack of structured and systematic information available, the aim of this study was to describe the epidemiology, diagnosis, healthcare processes, and treatment patterns of hereditary angioedema (HAE) in Mexico.

To achieve this, different data sources were consulted regarding medical literature, structured health system databases, and angioedema-specialized physicians (AEP) opinion regarding HAE.

MATERIAL AND METHODS: A mixed methods approach was conducted in 4 phases: I) systematic literature review (SLR) and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines; II) review of national health system (NHS) databases and systematic reports; III) physician survey; and IV) an epidemiologic model.

ICD 10 D84.1 encoded records from the NHS were used to estimate the number of patients with HAE attended and treated during 2019.

A survey was implemented to increase understanding of the clinical profile and treatments used.

RESULTS: A prevalence rate of 0.9/50 000 inhabitants was estimated for 2019.

In the same year, an estimated 317 HAE type 1 patients were recorded in the NHS, aged ≥11 years old.

The most frequent clinical symptoms were cutaneous edema (67.5%) and abdominal pain (47.9%).

A severe episode with laryngeal edema appeared in 27.5% of cases.

Acute episodes were mainly moderate to severe (77.0%), with an annual per capita frequency of emergency visits of 7.6 patient-year (range 1–12/patient-year).

The main reasons for hospitalization corresponded to laryngeal facial, tongue, and abdominal edemas, representing 73.3% of annual ICD 10 D84.1 reported hospitalizations.

The main treatments that patients with HAE received were fresh frozen plasma for acute attacks and danazol for short-term prophylaxis (STP).

CONCLUSIONS: Despite efforts to make HAE visible, according to this study, cases recognized and treated in the NHS represent only 16.6% of the estimated prevalence.